These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

497 related items for PubMed ID: 29467301

  • 21. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.
    Oncotarget; 2015 Nov 24; 6(37):40141-57. PubMed ID: 26472029
    [Abstract] [Full Text] [Related]

  • 22. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M, Tago K, Abe M, Sonoda Y, Kasahara T.
    J Biol Chem; 2010 Feb 19; 285(8):5296-307. PubMed ID: 20028972
    [Abstract] [Full Text] [Related]

  • 23. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
    Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL.
    Sci Transl Med; 2018 Apr 11; 10(436):. PubMed ID: 29643232
    [Abstract] [Full Text] [Related]

  • 24. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J, Tago K, Kasahara T, Funakoshi-Tago M.
    Cell Signal; 2011 May 11; 23(5):849-56. PubMed ID: 21255641
    [Abstract] [Full Text] [Related]

  • 25. Exploration of the role of NKG2D ligands MICA and MICB in JAK2 V617F-positive myeloproliferative neoplasms.
    Ivanova M, Tsvetkova G, Lessichkova S, Gesheva N, Hadjiev E, Shivarov V.
    HLA; 2023 Aug 11; 102(2):168-178. PubMed ID: 37002719
    [Abstract] [Full Text] [Related]

  • 26. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
    Funakoshi-Tago M, Moriwaki T, Ueda F, Tamura H, Kasahara T, Tago K.
    Cell Signal; 2017 Feb 11; 31():41-57. PubMed ID: 28038963
    [Abstract] [Full Text] [Related]

  • 27. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms.
    Hu M, Xu C, Yang C, Zuo H, Chen C, Zhang D, Shi G, Wang W, Shi J, Zhang T.
    J Exp Clin Cancer Res; 2019 Feb 04; 38(1):49. PubMed ID: 30717771
    [Abstract] [Full Text] [Related]

  • 28. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M, Sumi K, Kasahara T, Tago K.
    PLoS One; 2013 Feb 04; 8(1):e52844. PubMed ID: 23300995
    [Abstract] [Full Text] [Related]

  • 29. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.
    Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW.
    Br J Haematol; 2013 Jan 04; 160(2):177-87. PubMed ID: 23157224
    [Abstract] [Full Text] [Related]

  • 30. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A.
    Br J Haematol; 2018 Jul 04; 182(1):78-85. PubMed ID: 29767839
    [Abstract] [Full Text] [Related]

  • 31. Acute myeloid leukemias with JAK2/STAT mutations are associated with PD-L1 upregulation.
    Chai J, Choudhuri J, Wang Q, Fang Y, Shi Y, Kamel J, Shah N, Sica RA, Kornblum N, Konopleva M, Mantzaris I, Shastri A, Gritsman K, Verma A, Goldfinger M, Goel S, Wang Y, Tian X.
    Leuk Lymphoma; 2023 Oct 04; 64(10):1662-1672. PubMed ID: 37424335
    [Abstract] [Full Text] [Related]

  • 32. JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β.
    Aoun C, Maslah N, Ganesan S, Salomao N, Gendron R, Awan Toor S, Letort G, Gou P, Bonnamy M, Parietti V, Kiladjian JJ, Giraudier S, Cassinat B.
    J Cell Mol Med; 2024 Oct 04; 28(20):e70138. PubMed ID: 39431551
    [Abstract] [Full Text] [Related]

  • 33. Neutrophil-specific expression of JAK2-V617F or CALRmut induces distinct inflammatory profiles in myeloproliferative neoplasia.
    Haage TR, Charakopoulos E, Bhuria V, Baldauf CK, Korthals M, Handschuh J, Müller P, Li J, Harit K, Nishanth G, Frey S, Böttcher M, Fischer KD, Dudeck J, Dudeck A, Lipka DB, Schraven B, Green AR, Müller AJ, Mougiakakos D, Fischer T.
    J Hematol Oncol; 2024 Jun 09; 17(1):43. PubMed ID: 38853260
    [Abstract] [Full Text] [Related]

  • 34. JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms.
    Lin CH, Kaushansky K, Zhan H.
    Blood Cells Mol Dis; 2016 Nov 09; 62():42-48. PubMed ID: 27865175
    [Abstract] [Full Text] [Related]

  • 35. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T, Kurosu T, Umezawa Y, Nogami A, Oshikawa G, Tohda S, Yamamoto M, Miura O.
    PLoS One; 2014 Nov 09; 9(1):e84746. PubMed ID: 24404189
    [Abstract] [Full Text] [Related]

  • 36. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Grisouard J, Shimizu T, Duek A, Kubovcakova L, Hao-Shen H, Dirnhofer S, Skoda RC.
    Blood; 2015 Mar 26; 125(13):2131-40. PubMed ID: 25595737
    [Abstract] [Full Text] [Related]

  • 37. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
    Lundberg P, Takizawa H, Kubovcakova L, Guo G, Hao-Shen H, Dirnhofer S, Orkin SH, Manz MG, Skoda RC.
    J Exp Med; 2014 Oct 20; 211(11):2213-30. PubMed ID: 25288396
    [Abstract] [Full Text] [Related]

  • 38. An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
    Grauslund JH, Holmström MO, Martinenaite E, Lisle TL, Glöckner HJ, El Fassi D, Klausen U, Mortensen REJ, Jørgensen N, Kjær L, Skov V, Svane IM, Hasselbalch HC, Andersen MH.
    Front Immunol; 2023 Oct 20; 14():1117466. PubMed ID: 36911725
    [Abstract] [Full Text] [Related]

  • 39. miR-375 inhibits IFN-γ-induced programmed death 1 ligand 1 surface expression in head and neck squamous cell carcinoma cells by blocking JAK2/STAT1 signaling.
    Wu Q, Zhao Y, Sun Y, Yan X, Wang P.
    Oncol Rep; 2018 Mar 20; 39(3):1461-1468. PubMed ID: 29328389
    [Abstract] [Full Text] [Related]

  • 40. Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms.
    Grimwade LF, Happerfield L, Tristram C, McIntosh G, Rees M, Bench AJ, Boyd EM, Hall M, Quinn A, Piggott N, Scorer P, Scott MA, Erber WN.
    Br J Haematol; 2009 Nov 20; 147(4):495-506. PubMed ID: 19747364
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.